scholarly journals Pulsed Electromagnetic Field Assisted in vitro Electroporation: A Pilot Study

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Vitalij Novickij ◽  
Audrius Grainys ◽  
Eglė Lastauskienė ◽  
Rūta Kananavičiūtė ◽  
Dovilė Pamedytytė ◽  
...  
Keyword(s):  
Electromagnetic Field ◽  
Pilot Study ◽  
Pulsed Electromagnetic Field ◽  
Pulsed Electromagnetic

scholarly journals AB0958 LOW-ENERGY PULSED ELECTROMAGNETIC FIELD THERAPY REDUCES PAIN IN FIBROMYALGIA: A RANDOMIZED SINGLE-BLIND CONTROLLED PILOT STUDY.

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1776.2-1776
Author(s):  
M. Giovale ◽  
L. Novelli ◽  
S. Rampoldi ◽  
R. Galli ◽  
P. Monteforte ◽  
...  
Keyword(s):  
Electromagnetic Field ◽  
Pilot Study ◽  
Symptom Severity ◽  
Low Energy ◽  
Widespread Pain ◽  
Pulsed Electromagnetic Field ◽  
Research Support ◽  
Sf 36 ◽  
Pulsed Electromagnetic ◽  
Single Blind

Background:Fibromyalgia is a clinical condition characterized by diffuse chronic muscle-skeletal pain, fatigue, sleep/mood disorders and muscular stiffness. The pathogenesis of fibromyalgia remains poorly understood but numerous lines of evidence suggest a role for alterations of both the central and peripheral nervous systems leading to heightened pain sensitivity along with acorollariumof other symptoms1. Low-energy pulsed electromagnetic field (PEMF) has promising data in the prevention of falls in senior individuals and is believed to promote osteogenesis and angiogenesis thus proving promising to treat bone diseases with chronic pain2. No data is available in fibromyalgia.Objectives:To investigate the efficacy and safety of PEMF on fibromyalgia symptoms in a randomized single-blind pilot study.Methods:We enrolled 21 women (median age 59 years, IQR 16,5) affected by fibromyalgia according to the 2010 ACR classification criteria3not receiving chronic medical treatment for pain; patients were randomly allocated to receive PEMF TEPT (triple energy pain treatment) / New Sunrise 280 (THS - Therapeutic Solutions, Milan, Italy) on the selected points (10 agopuncture points) or scrambled points for 20 minutes at baseline (T0) and after 4 (T4) and 8 (T8) weeks. Outcome measures were recorded at T0, T4 and T8 and included FIQ (fibromyalgia impact questionnaire), WIP (widespread pain index), VAS pain, SS (symptom severity scale), and SF-36 (short form 36 health survey questionnaire).Results:Patients receiving the active treatment had a deep reduction of WIP from T0 to T8 (-76% vs -13% in placebo) with a statistically significant difference compared to the placebo group (p=0.0025) (Figure 1). In all endpoints, we observed a general reduction at T4 and T8 compared to T0 also for FIQ, VAS pain, SS, SF-36, regardless of the treatment arm and the decrease was higher in the active treatment arm compared to the placebo group, albeit not reaching statistical significance (Figure 2).Conclusion:The results of our pilot study show that PEMF is more effective than placebo in reducing widespread pain in fibromyalgia while confirming that a placebo effect is clear in this complex disease.References:[1]Targeting network hubs with noninvasive brain stimulation in patients with fibromyalgia Chelsea M. Kaplan, R.E. Harris, UnCheol Lee, Alexander F. DaSilva, George A. Mashour, Steven E. Harte. PAIN: January 2020 - Volume 161 - Issue 1 - p 43-46[2]Yuan J, Xin F, Jiang W. Underlying Signaling Pathways and Therapeutic Applications of Pulsed Electromagnetic Fields in Bone Repair.Cell Physiol Biochem. 2018;46(4):1581-1594[3]Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken).2010;62:600-61Disclosure of Interests:Massimo Giovale: None declared, Lucia Novelli: None declared, Stefano Rampoldi: None declared, Rossana Galli: None declared, Patrizia Monteforte: None declared, Marica Doveri: None declared, Gerolamo Bianchi Grant/research support from: Celgene, Consultant of: Amgen, Janssen, Merck Sharp & Dohme, Novartis, UCB, Speakers bureau: Abbvie, Abiogen, Alfa-Sigma, Amgen, BMS, Celgene, Chiesi, Eli Lilly, GSK, Janssen, Medac, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sanofi Genzyme, Servier, UCB, Luigi Carlo Bottaro: None declared, Carlo Selmi Grant/research support from: AbbVie, Janssen, MSD, Novartis, Pfizer, Celgene, and Leo Pharma, Consultant of: Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and Sanofi-Regeneron, Speakers bureau: AbbVie, Aesku, Alfa-Wassermann, Bristol-Myers Squibb, Biogen, Celgene, Eli-Lilly, Grifols, Janssen, MSD, Novartis, Pfizer, Roche, Sanofi-Genzyme, UCB Pharma

Antimicrobial effects of a pulsed electromagnetic field: an in vitro polymicrobial periodontal subgingival biofilm model

Biofouling ◽  
2020 ◽  
Vol 36 (7) ◽  
pp. 862-869
Author(s):  
Marcelo Faveri ◽  
Danilo Eduardo Calgaro Miquelleto ◽  
Bruno Bueno-Silva ◽  
João Marcos Spessoto Pingueiro ◽  
Luciene Cristina Figueiredo ◽  
...  
Keyword(s):  
Electromagnetic Field ◽  
Pulsed Electromagnetic Field ◽  
Antimicrobial Effects ◽  
Biofilm Model ◽  
Pulsed Electromagnetic

DNA damage in frog erythrocytes after in vitro exposure to a high peak-power pulsed electromagnetic field

2004 ◽  
Vol 558 (1-2) ◽  
pp. 27-34 ◽  
Author(s):  
Nikolai K. Chemeris ◽  
Andrew B. Gapeyev ◽  
Nikolai P. Sirota ◽  
Olga Yu. Gudkova ◽  
Natalia V. Kornienko ◽  
...  
Keyword(s):  
Dna Damage ◽  
Electromagnetic Field ◽  
Peak Power ◽  
High Peak ◽  
High Peak Power ◽  
Pulsed Electromagnetic Field ◽  
In Vitro Exposure ◽  
Pulsed Electromagnetic

Use of a pulsed electromagnetic field for treatment of post–operative pain in dogs: a pilot study

2002 ◽  
Vol 29 (1) ◽  
pp. 43-48 ◽  
Author(s):  
Heidi L Shafford ◽  
Peter W Hellyer ◽  
Kenneth T Crump ◽  
Ann E Wagner ◽  
Khursheed R Mama ◽  
...  
Keyword(s):  
Electromagnetic Field ◽  
Pilot Study ◽  
Pulsed Electromagnetic Field ◽  
Post Operative Pain ◽  
Pulsed Electromagnetic
Sign in / Sign up

Export Citation Format

Share Document